1. R117H-CFTR function and response to VX-770 correlate with mRNA and protein expression in intestinal organoids.
- Author
-
Van Mourik P, van Haaren P, Kruisselbrink E, Korkmaz C, Janssens HM, de Winter-de Groot KM, van der Ent CK, Hagemeijer MC, and Beekman JM
- Subjects
- Cell Culture Techniques, Colon metabolism, Cystic Fibrosis drug therapy, Cystic Fibrosis pathology, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Cystic Fibrosis Transmembrane Conductance Regulator metabolism, Humans, Organoids metabolism, RNA, Messenger metabolism, Aminophenols pharmacology, Chloride Channel Agonists pharmacology, Colon drug effects, Cystic Fibrosis metabolism, Cystic Fibrosis Transmembrane Conductance Regulator drug effects, Organoids drug effects, Quinolones pharmacology
- Abstract
Introduction: Variability in disease severity and CFTR modulator responses exists between patients with identical CFTR genotypes. Here, we characterized transcription, translation and function of R117H-CFTR using intestinal organoids and correlated them with in vitro responses to ivacaftor (VX-770)., Methods: Organoids were generated from individuals possessing at least one R117H-CFTR allele. The forskolin-induced swelling (FIS) assay was used to measure CFTR function and response to VX-770 treatment. R117H-CFTR protein and mRNA expression levels were determined in parallel and Pearson's correlation coefficients were assessed., Results: Variability in R117H-CFTR FIS responses was observed and correlated significantly with mRNA and protein expression. Response to VX-770 treatment in organoids correlated with mRNA and protein expression as well., Conclusions: Our results indicate that gene expression, protein expression and CFTR function are strongly correlated in organoids from people with CFTR-R117H-7T/9T, which may suggest that CFTR gene expression may have consequences for CF diagnosis, prognosis and therapeutic benefit., Competing Interests: Declaration of Competing Interest Cornelis K. van der Ent reports grants from GSK, Nutricia, TEVA, Gilead, Vertex, ProQR, Proteostasis, Galapagos NV, and grants from Eloxx outside the submitted work and has a patent 10006904 with royalties paid. Prof. Dr. Beekman has a patent on organoid swelling for personalized diagnosis in CF with royalties paid to Hubrecht Organoid Technology and received financial support to cover travel costs and preparation time of scientific lectures from Vertex Pharmaceuticals. He also received funding from Galápagos NV for CFTR modulator studies., (Copyright © 2020 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF